Back to search results

Lurbinectedin with Paclitaxel and Bevacizumab for Ovarian Cancer

This study is looking at whether adding lurbinectedin to the combination of paclitaxel and bevacizumab can help control advanced ovarian cancer that has become resistant to platinum-based chemotherapy. Researchers want to find the safest dose of this three-drug combination and see how well it works. They will also look at how the treatment affects certain cells in the body called macrophages. The study aims to enroll 34 women, aged 18 or older, who have platinum-resistant ovarian cancer. Success will be measured by how many side effects occur and how well the cancer responds to treatment. The current recruitment status is unclear.

Study design
This is an interventional study with a planned enrollment of 34 participants. It is a Phase 1b study, meaning it focuses on safety and finding the right dose of the drug combination.
What's involved
You would need to provide signed informed consent and be able to follow the study protocol, including undergoing treatment and scheduled visits for the duration of the study.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for adverse events through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05636111

Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

Recruiting
PHASE1Ages 18+InterventionalTreatment
M.D. Anderson Cancer Center
~34 participants
Updated 2026-08-20 on ClinicalTrials.gov
What's tested:PaclitaxelBevacizumabLurbinectedin

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Measured over through study completion; an average of 1 year.

Conditions

Ovarian Cancer

Explore related trials

Malignant Ovarian Neoplasm

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Shannon Westin, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Shannon Westin, MD
[email protected]
713-794-4314
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Platinum refractory is defined as progression during platinum-containing therapy or within 4 weeks of last dose.
Platinum resistant is defined as relapse-free interval 1-6 months of a platinum-containing therapy 5. Prior Therapy: Unlimited prior systemic therapies are allowed. 6. ECOG performance status of 0-1 (Appendix A) 7. Adequate normal organ and marrow function as defined below.

What this trial measures

  • Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0through study completion; an average of 1 year.